Vaxcyte’s VAX-31 Meets All Key Endpoints in Phase 3 Trial, Setting Stage for FDA Review

  • Vaxcyte’s VAX-31 met all prespecified primary endpoints in the OPUS-1 Phase 3 trial, including noninferiority and superiority criteria across age groups.
  • The vaccine demonstrated a safety profile similar to existing pneumococcal vaccines (PCV20 and PCV21) across all ages studied.
  • Vaxcyte plans to report results from OPUS-2 and OPUS-3 trials in the first half of 2027, with a Biologics License Application submission expected in the first half of 2028.
  • VAX-31 is designed to cover approximately 95% of invasive pneumococcal disease and 88% of pneumococcal pneumonia in U.S. adults aged 50 and older.

Vaxcyte’s positive Phase 3 results for VAX-31 mark a significant step in the race to develop a next-generation pneumococcal vaccine. The broader coverage and robust immune responses demonstrated in the trial could set a new benchmark for the class, addressing critical gaps in adult pneumococcal disease coverage. The strategic anomaly here is the company’s ability to deliver a 31-valent vaccine while maintaining the magnitude of immune responses, a challenge that has limited competitors.

Regulatory Pathway
Whether the FDA will accept the OPUS-1 data as sufficient for approval, given the stringent noninferiority standards applied.
Market Positioning
How VAX-31’s broader coverage and robust immune responses will position it against existing vaccines like PCV20 and PCV21.
Execution Risk
The pace at which Vaxcyte can complete the remaining trials and manufacturing consistency studies to meet the 2028 BLA submission timeline.